Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 8/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 5/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 3/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | EPHB3 | P54753 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 1/20 | 1.00 |
| ▸ | PRKACG | P22612 | 1/20 | 1.00 |
| ▸ | PRKACB | P22694 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 7/20 | 0.52 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5809941 | 1.00 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5809951 | 1.00 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5772118 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5772113 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5811223 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL30737868 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5832196 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL30737937 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL27218145 | 0.92 | EGFR (1.00) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5830349 | 0.91 | EGFR (0.83) | EGFRFGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | claimed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | claimed |
| WO-2023240271-A1 | USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY | FOUNTAIN THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | claimed |
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12415989-B2 | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs | FATE THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-114164167-B | Cell culture platform for single cell sorting and enhanced IPSC reprogramming | 菲特治疗公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-114164167-A | Cell culture platform for single cell sorting and enhanced IPSC reprogramming | 菲特治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | GSK3B, GSK3A, WNT3A | EGFR 1606/4885FGFR4 130/4885FGFR1 266/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | EGFR 475/4885FGFR4 8/4885FGFR1 1/4885 |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | EGFR 41/4885FGFR4 3/4885FGFR1 2/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | EGFR 29/4885FGFR4 84/4885FGFR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.